Singapore Medical Device Regulatory Updates in 2026

1. Key takeaways

Singapore’s medical device regulations went through a dense round of updates in 2026, centred on five instruments: GN-15 R13 (10 March 2026) — introducing reliance on Malaysia’s MDA; GN-15 R14 (14 September 2026) — adding Annex 4 label / AE / FSCA declarations; GN-15 R15 (October 2026) with GN-17 R5 / GN-18 R5 updated in step; GN-21 R7 (1 August 2026) — clarifying change classification and limiting each product listing to at most two changes under assessment; and GN-02 R8 (1 April 2026) — requiring an audit report to be submitted together with the QMS certificate.

• Three GN-15 revisions in one year mark Singapore as an unusually active regulatory environment.
• The common direction of the changes is front-loaded disclosure of information at submission.
• The two-changes-under-assessment cap in GN-21 R7 reshapes iteration pacing for software products.
• UDI Phase 2 (1 November 2026) brings all Class C general devices and IVDs into mandatory UDI.

2. Legal basis

The 2026 update landscape is summarised in the following table, together with the practical impact of each change on active and planned projects.

Note: the specific clause wording of R13/R14 follows the official HSA GN-15 text; the current applicable version is R15 (October 2026).

3. Expert insights

Five observations on what this update cycle means for manufacturers and their filings.

Insight 1: three GN-15 revisions within one year signal that Singapore is in an active rulemaking phase. This density is rare among Southeast Asian markets. For projects already in flight, it means the version your dossier was written against must be re-verified; for projects not yet started, it means downloading the entire latest guidance set at kickoff is mandatory — old templates cannot be reused.

Insight 2: the common direction of the three changes is front-loaded disclosure. Read together — Annex 4 of R14 (proactive disclosure of labelling differences and AE/FSCA history), GN-02 R8 (submission of audit reports), and GN-15 R13 (reliance requires identical intended use) — the direction is clear: HSA is moving the cost of after-the-fact checks forward into self-declaration at submission. This favours honest declarants, whose processes get faster, and disfavours those who attempt to blur the picture.

Insight 3: the two-changes-under-assessment cap in GN-21 R7 changes the product iteration rhythm. This rule hits software and fast-iterating product lines hardest. The answer is not to make fewer changes, but to use the Change Management Plan (CMP) under GN-37 R1 to pre-admit foreseeable iterations, so they can proceed through lighter channels instead of queueing behind the cap.

Insight 4: UDI Phase 2 lands in the same window, creating stacked pressure. From 1 November 2026, Class C devices enter mandatory UDI. For a Class C project starting now, documents must be prepared to R15/R5 while UDI-DI registration proceeds in parallel. The two workstreams must run in parallel, not in series — serialising them leaves the project stuck at either the filing or the device identification step.

Insight 5: the institutional landscape is also shifting. An official HSA announcement (9 September 2026) proposed the Health Sciences Authority (Amendment) and Other Matters Bill, with a direction of consolidating health regulatory functions. This is an institutional variable that needs continuous tracking, as it may affect future process entry points and system platforms.

4. Practical recommendations

We recommend the following measures to keep projects aligned with the 2026 update cycle.

1. Download the entire latest guidance set at kickoff: GN-15 R15 plus GN-17/GN-18 R5, the e-submission guide and the configuration checklist.
2. Run a version review for in-flight projects: confirm the dossier version matches the current version.
3. Request the QMS audit report early (GN-02 R8).
4. Advance UDI and registration in parallel for Class C projects (1 November 2026 milestone).
5. Use a CMP to relieve the change queue for software products (GN-37 R1 plus GN-21 R7).
6. Establish a quarterly version check: review the HSA guidance documents page at least once per quarter.

Regulatory information verified as of: 26 October 2026

Source level: Tier 2 (HSA guidance documents page; official HSA announcements), Tier 3 (industry compilation of specific R13/R14 clause wording, subject to official texts)

5. Verification checklist

• □ The entire latest guidance set has been downloaded (GN-15 R15, GN-17/GN-18 R5, e-submission guide R5, Annex 2)
• □ Version review completed for in-flight projects
• □ QMS audit report obtained (GN-02 R8)
• □ Change queue re-sequenced under the two-under-assessment cap (GN-21 R7)
• □ UDI workstream started in parallel for Class C projects
• □ CMP prepared for software products (GN-37 R1)
• □ Quarterly version check mechanism established
• □ HSA institutional consolidation developments tracked

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com